BioAge Bets Its $350 Million War Chest on ‘Inflammaging’ as New Mouse Research Shows Exercise Can Switch Off the Heart’s Inflammatory Aging Program

For years, “inflammaging” was a word longevity researchers used to describe a pattern: as people get older, a low, steady hum of inflammation builds up in the body and seems to feed heart disease, diabetes, eye disease and frailty. This week, two very different pieces of news turned that idea into something closer to a business thesis. On one side, BioAge Labs told investors it has more than $350 million in cash to test whether a pill that shuts down an upstream inflammation switch can treat age-related disease. On the other, new mouse research suggests that plain old exercise turns down much of the inflammatory “aging program” that builds up in the heart.

Put together, they sketch where the healthy-aging market is heading: away from vague anti-aging promises and toward measurable inflammation targets that drug makers, clinics and employers can actually track.

BioAge’s Pitch: Go Upstream of the Fire

Speaking at the Guggenheim Healthcare Innovation Conference on November 10, BioAge co-founder and CEO Kristen Fortney laid out a strategy built on what the company describes as up to 50 years of longitudinal blood samples from people who were healthy and middle-aged when the samples were first taken, according to an Investing.com summary and transcript of the session. The company says it links proteins and metabolites in those samples to later outcomes such as lifespan, physical function and cognition, then hunts for drug targets.

Its lead drug, BGE-102, is a brain-penetrant inhibitor of NLRP3, a protein complex that sits near the top of the inflammatory cascade and drives the release of the signaling molecule IL-1β. BioAge said Phase I data showed up to a 98% reduction in IL-1β and an 86% reduction in CRP, a common blood marker of inflammation, with tolerability similar to placebo.

The drug is now in two Phase II studies:

• QUELL-CV, a 180-patient study in people with obesity and high baseline inflammation, testing 30 mg, 60 mg and 90 mg once daily for three months. Fortney described the readout as imminent.
• QUELL-DME, in diabetic macular edema, which BioAge said it upgraded from a biomarker study to a true efficacy trial powered on an approvable vision endpoint, with results expected next year.

Fortney argued that the recent failure of the ZEUS cardiovascular trial, which targeted IL-6, shows the problem with hitting inflammation too far downstream. NLRP3, she said, sits above IL-1β, IL-6 and IL-18, giving one drug a chance to affect several disease pathways at once. BioAge also pointed to partnerships with Eli Lilly and Novartis, the latter focused on the overlap between aging biology and the body’s response to exercise.

The market is not yet convinced. Investing.com reported BioAge’s market capitalization at about $261.5 million, with the stock down 68% over six months to $5.79. That means the company’s cash pile is worth more than the whole business in the eyes of investors, a classic sign that Wall Street wants proof before it pays for a platform story.

The Exercise Study: Inflammation Keeps Aging’s Switches On

The second piece of news comes from a preprint by researchers at Memorial Sloan Kettering Cancer Center in New York and the Victor Chang Cardiac Research Institute in Sydney, summarized on November 11 by The Long Run. The team had mice run on a treadmill for 45 minutes a day, five days a week, for six months, and then read gene activity and DNA accessibility in more than 116,000 individual heart-cell nuclei.

The findings line up neatly with the inflammaging thesis:

• Aging increased binding of AP-1, a stress- and inflammation-responsive family of gene regulators, at more than 100,000 DNA “switch” sites across heart cell types, and exercise opposed most of those gains.
• Of 176 genes that clearly changed with age, 167, or about 95%, moved back the other way in exercised mice. Inflammation and scarring programs were the most prominent.
• A gene-activity clock judged exercised hearts about two to three months younger than sedentary ones.
• The inflammatory messenger IL-1β pulled AP-1 onto the age-gained switches, and neutralizing IL-1β in old mice for five weeks dimmed those same switches and shifted gene activity in the same direction as exercise.

There are important caveats. This is mouse work that has not been peer-reviewed, several experiments used small groups, and the five-week IL-1β block did not clearly improve heart function, even though short-term training in very old mice did reduce collagen build-up and improve how heart muscle contracted. The authors’ takeaway is that part of how the heart ages appears to depend on an ongoing inflammatory signal, which leaves room to change it late in life.

Why It Matters for Business Readers

The target is converging. The mouse study points at IL-1β as one of the signals keeping aging’s switches on. BioAge’s drug is built to cut IL-1β production at its source. Neither result proves the other, but it is the kind of overlap between basic biology and a clinical pipeline that investors in longevity look for, and it helps explain why Novartis is paying to study aging and exercise biology together.

Aging still is not a disease on paper. BioAge is testing BGE-102 in obesity-linked inflammation and diabetic eye disease, not “aging.” That is how the sector has to operate while regulators lack validated endpoints for biological age. Companies that win will be the ones that turn longevity science into ordinary, reimbursable indications first.

Exercise is the benchmark to beat. If a moderate running habit can reverse roughly 95% of the age-linked gene changes measured in a mouse heart, any drug, supplement or clinic program selling heart health will be judged against it. For employers and insurers, that strengthens the case for funding activity programs, and for wellness brands it is a reminder that claims will increasingly be measured with biomarkers like CRP and IL-1β.

The near-term catalyst is real. QUELL-CV data, which Fortney said is coming soon, will be one of the clearest tests yet of whether an upstream inflammation drug can deliver deep, dose-dependent biomarker cuts over three months in a high-risk group. A strong result could reset sentiment toward the whole inflammaging category; a weak one would reinforce the market’s skepticism.

The Bottom Line

Inflammaging is moving from theory to test. A well-funded biotech is about to show whether a pill can switch off chronic inflammation at its source, while lab research suggests the body’s own response to exercise already does much of that work in the heart. For now, the cheapest longevity intervention remains a pair of running shoes. The next few quarters will show whether there is a prescription that can compete.

Sources: Investing.com, BioAge at Guggenheim conference (Nov 10, 2026); The Long Run, exercise and aging switches in the mouse heart (Nov 11, 2026).

Edited by Coron @QUE.COM
Website: https://QUE.COM Intelligence
Sponsored by: https://MAJ.COM AI Autonomous